BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 18, 2026
Home » Authors » Cormac Sheridan

Cormac Sheridan

Articles

ARTICLES

GSK, UCC Enter €13.7M Deal For Gastrointestinal Disease

Aug. 30, 2006
By Cormac Sheridan

NeuroSearch Buys Carlsson Research In SEK875M Deal

Aug. 30, 2006
By Cormac Sheridan
In its first foray into the capital markets in five years, NeuroSearch aims to raise DKK350 million (US$60.1 million) to DKK 400 million in a rights issue to support its planned acquisition of A. Carlsson Research AB in a combined cash and shares deal valued at up to SEK875 million (US$121.2 million). (BioWorld International)
Read More

GSK, UCC Enter €13.7M Deal For Gastrointestinal Disease

Aug. 30, 2006
By Cormac Sheridan
No Abstract
Read More

NeuroSearch Buys Carlsson Research In SEK875M Deal

Aug. 30, 2006
By Cormac Sheridan
In its first foray into the capital markets in five years, NeuroSearch aims to raise DKK350 million (US$60.1 million) to DKK 400 million in a rights issue to support its planned acquisition of A. Carlsson Research AB in a combined cash and shares deal valued at up to SEK875 million (US$121.2 million). (BioWorld International)
Read More

4-Antibody Gets CHF6M For Antibody Drug Development

Aug. 23, 2006
By Cormac Sheridan

Speedel Gains Rights To SPP200; Abbott Declines

Aug. 23, 2006
By Cormac Sheridan

MerLion Buys Combinature, Athelas In Three-Way Merger

Aug. 23, 2006
By Cormac Sheridan
The Singapore-based company also banked $25 million, which represents the first closing of a $30 million venture capital round led by Aravis Venture Associates AG, of Zurich, Switzerland, and Bio*One Capital Pte. Ltd., of Singapore. (BioWorld International)
Read More

MerLion Buys Combinature, Athelas In Three-Way Merger

Aug. 23, 2006
By Cormac Sheridan
The Singapore-based company also banked $25 million, which represents the first closing of a $30 million venture capital round led by Aravis Venture Associates AG, of Zurich, Switzerland, and Bio*One Capital Pte. Ltd., of Singapore. (BioWorld International)
Read More

Speedel Gains Rights To SPP200; Abbott Declines

Aug. 23, 2006
By Cormac Sheridan

4-Antibody Gets CHF6M For Antibody Drug Development

Aug. 23, 2006
By Cormac Sheridan
View All Articles by Cormac Sheridan

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing